![Michael Giordano](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael Giordano
Keine laufenden Positionen mehr
Profil
Michael F.
Giordano served as Senior Vice President & Head-Oncology Development at Bristol Myers Squibb Co. from 2012 to 2017.
He was Non-Executive Director at Achilles Therapeutics UK Ltd. from 2018 to 2021 and Independent Non-Executive Director at Achilles Therapeutics Plc from 2018 to 2024.
He held the position of Independent Director at Rapt Therapeutics, Inc. from 2018 to 2026.
He was Director at Epizyme, Inc. from 2018 to 2022 and Director at Oncovalent Therapeutics, Inc. from 2020 to 2023.
He worked as Assistant Professor at the National Institutes of Health and Weill Cornell Medicine.
Dr. Giordano completed undergraduate studies at The Johns Hopkins University and earned a doctorate from Weill Cornell Medicine.
Ehemalige bekannte Positionen von Michael Giordano
| Unternehmen | Position | Ende |
|---|---|---|
| RAPT THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 03.03.2026 |
| ACHILLES THERAPEUTICS PLC | Direktor/Vorstandsmitglied | 01.12.2024 |
Oncovalent Therapeutics, Inc.
 Oncovalent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops immuno oncology drugs and therapeutics | Direktor/Vorstandsmitglied | 01.12.2023 |
| EPIZYME, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.08.2018 |
Achilles Therapeutics UK Ltd.
 Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer | Direktor/Vorstandsmitglied | 11.01.2021 |
Ausbildung von Michael Giordano
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
83
Beziehungen ersten Grades
9
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 9 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
The Johns Hopkins University
 The Johns Hopkins University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
National Institutes of Health
 National Institutes of Health General GovernmentGovernment Engages in the improvement of health and saving lives | Government |
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Develops therapeutics for the treatment of patients with genetically defined cancers | Health Technology |
Rapt Therapeutics, Inc.
 Rapt Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes oral small molecule therapies for patients | Health Technology |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer | Health Technology |
Weill Cornell Medicine
 Weill Cornell Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Achilles Therapeutics Plc
 Achilles Therapeutics Plc Pharmaceuticals: MajorHealth Technology Develops and sells cancer immunotherapies | Health Technology |
Oncovalent Therapeutics, Inc.
Oncovalent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops immuno oncology drugs and therapeutics | Health Technology |
